The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.
Exscientia, a UK-based drug discovery technology developer that counts several corporates among its investors, closed its initial public offering at just over $350m yesterday.
The company floated in an upsized IPO last week, issuing more than 13.8 million shares priced at the top of its $20 to $22 range. Telecommunications and internet group SoftBank’s Vision Fund 2 and Bill and Melinda Gates Foundation added $160m in a private placement.
Joint book-running managers Goldman Sachs, Morgan Stanley, BofA Securities and…
